-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
3M-011
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/642473-62-9.gif)
| Category | Influenza Virus |
| CAS | 642473-62-9 |
| Description | 3M-011, a potent dual toll-like receptor TLR7/8 agonist and cytokine inducer, is a potent radiotherapy adjuvant that induces local and profound systemic immune responses during radiotherapy. 3M-011 significantly inhibits the replication of H3N2 influenza virus in the nasal cavity, and has a strong anti-tumor effect. |
Product Information
| Synonyms | Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]-; N-[2-[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide; 3M 011; 3M011; 3M 854A; N-(1-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-yl)methanesulfonamide |
| IUPAC Name | N-[1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-yl]methanesulfonamide |
| Molecular Weight | 391.49 |
| Molecular Formula | C18H25N5O3S |
| Canonical SMILES | CCOCC1=NC2=C(N1CC(C)(C)NS(=O)(=O)C)C3=CC=CC=C3N=C2N |
| InChI | InChI=1S/C18H25N5O3S/c1-5-26-10-14-21-15-16(12-8-6-7-9-13(12)20-17(15)19)23(14)11-18(2,3)22-27(4,24)25/h6-9,22H,5,10-11H2,1-4H3,(H2,19,20) |
| InChIKey | NVNWHRIYBUUBAJ-UHFFFAOYSA-N |
| Boiling Point | 624.7±65.0°C at 760 mmHg |
| Flash Point | 331.6±34.3 °C |
| Purity | ≥95% |
| Density | 1.4±0.1 g/cm3 |
| Solubility | Soluble in DMSO |
| Appearance | Solid |
| Storage | Store in a cool and dry place and at 2-8°C for short term (days to weeks) or -20°C for long term (months to years) |
| Complexity | 609 |
| Exact Mass | 391.167816 |
| Index Of Refraction | 1.643 |
| In Vitro | 3M-011 (0-100 μg/mL; 24 hours; B16-F10 melanoma cells) treatment can decrease B16-F10 melanoma cell counts. It potentiates natural killer (NK) cells cytotoxicity. The NF-κB reporter is stably integrated into HEK-293 cells that are subsequently transiently transfected with human or mouse TLR7 or TLR8. With all the TLRs tested, except mouse TLR8, stimulation with 3M-011 results in a dose-dependent induction of NF-κB-controlled luciferase activity. 3M-011 in humans activates both TLR7 and TLR8, whereas in mice, 3M011 activates only TLR7 and not TLR8. |
| In Vivo | 3M-011 treatment shows antitumor effects in scid/NOD mice bearing B16-F10 cells. Wild-type C57BL/6 mice are injected subcutaneously with different doses of 3M-011. 3M-011 induces a dose-dependent increase in serum concentrations of both TNF-α and IFN-α/β. Animal Model: Female scid/NOD mice (8-12-week-old) injected with B16-F10 cells. |
| Target | TLR7; TLR8; H3N2 influenza viral |
| Vapor Pressure | 0.0±1.8 mmHg at 25°C |
| XLogP3-AA | 1.1 |
